To clarify the underlying pharmacological mechanism of BAC on anti-hypertension by targeting ACE/ACE2, we further studied the endothelium-dependent vasorelaxation and vascular inflammation in BAC-treated SHRs. Here, ACE is linked to hypertensive disorder.